Review of VTE risk with JAK inhibitors - Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk
Tweet Content
Review of VTE risk with JAK inhibitors
- Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk factors, VTE 0.35/100PY
- Baricitinib: IR of DVT/PE was 0.5/100PY
- Filgotinib: 200mg VTEs 0.2/100PY
Most VTE occured in LT extension of RCT https://t.co/xvf0kQUMel https://t.co/Bj6fmkktP7
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off